塞拉万斯生物制药 TBPH
$0.00 +$0.00 (0.00%)
休市 · Oct 24, 12:40 am ET
开盘$0.00
昨收$0.00
当日区间$0.00 – $0.00
成交量0.00
市值$884.18M
市盈率（TTM）16.4
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$20.73M-20.9% YoY
营业利润$1.84M+167.6% YoY
净利润-$5.90M-110.8% YoY
摊薄每股收益-$0.11-110.2% YoY
自由现金流-$6.97M-103.3% YoY
经营现金流-$6.97M
营收，近8个季度
净利润，近8个季度
各季度摊薄每股收益
各季度自由现金流
年度营收
盈利能力与资产负债表
营业利润率9.2%
净利率51.6%
净资产收益率20.9%
资产收益率12.0%
投入资本回报率14.0%
流动比率13.54
负债/资产比率38.3%
现金及投资$387.66M
总负债$27.77M
净现金（净负债）$359.88M
自由现金流/营收51.5%
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 报告营业总收入 | $20.73M | $17.70M | $107.46M | $45.89M | $19.99M |
| 营业总收入 | $20.73M | $17.70M | $107.46M | $45.89M | $19.99M |
| 营业费用 | $18.89M | $23.55M | $111.07M | $25.88M | $26.45M |
| 销售及管理费用 | $14.18M | $17.72M | $73.65M | $18.52M | $18.33M |
| 研发费用 | $4.71M | $5.83M | $37.41M | $7.36M | $8.11M |
| 营业利润 | $1.84M | -$5.85M | -$3.60M | $20.01M | -$6.46M |
| 非经营性利息净收入（支出） | $3.49M | $3.01M | $7.71M | $3.06M | $3.57M |
| 非经营性利息收入 | $3.49M | $3.01M | $10.17M | $3.64M | $4.14M |
| 非经营性利息支出 | $0.00 | $0.00 | $2.46M | $582,000.00 | $573,000.00 |
| 其他收入（支出） | -$10.12M | -$3.63M | $125.14M | $50.00M | – |
| 特殊收益（费用） | -$10.12M | -$3.63M | $75.14M | $0.00 | $0.00 |
| -减：重组及并购费用 | $10.12M | $3.63M | – | – | – |
| -固定资产出售收益 | $0.00 | – | $75.14M | $0.00 | $0.00 |
| 税前利润 | -$4.79M | -$6.47M | $129.25M | $73.07M | -$2.89M |
| 税费 | $1.11M | -$1.54M | $23.35M | $12.04M | -$6.50M |
| 净利润 | -$5.90M | -$4.93M | $105.90M | $61.02M | $3.62M |
| 持续经营利润 | -$5.90M | -$4.93M | $105.90M | $61.02M | $3.62M |
| 归属母公司净利润 | -$5.90M | -$4.93M | $105.90M | $61.02M | $3.62M |
| 归属普通股股东净利润 | -$5.90M | -$4.93M | $105.90M | $61.02M | $3.62M |
| 基本每股收益 | -$0.11 | -$0.10 | $2.10 | $1.20 | $0.07 |
| 摊薄每股收益 | -$0.11 | -$0.10 | $2.06 | $1.15 | $0.07 |
| -减：资本性资产减值 | – | – | $0.00 | $0.00 | $0.00 |
| 其他非经营性收入（支出） | – | – | $50.00M | – | – |
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 总资产 | $469.77M | $472.31M | $485.57M | $485.57M | $415.46M |
| 流动资产合计 | $416.66M | $417.63M | $418.46M | $418.46M | $354.70M |
| 现金及现金等价物与短期投资 | $387.66M | $394.67M | $315.36M | $315.36M | $329.68M |
| -现金及现金等价物 | $219.77M | $288.10M | $167.81M | $167.81M | $174.77M |
| -短期投资 | $167.89M | $106.57M | $147.55M | $147.55M | $154.91M |
| 应收款 | $20.38M | $15.58M | $95.54M | $95.54M | $18.27M |
| -应收账款 | $20.38M | $15.58M | $45.54M | $45.54M | $18.27M |
| 其他流动资产 | $8.62M | $7.38M | $7.56M | $7.56M | $6.75M |
| 非流动资产合计 | $53.11M | $54.68M | $67.11M | $67.11M | $60.76M |
| 固定资产净值 | $27.10M | $28.54M | $30.27M | $30.27M | $31.71M |
| -固定资产原值 | $27.10M | $28.54M | $54.09M | $54.09M | $31.71M |
| 投资及预付款 | $0.00 | $0.00 | $11.13M | $11.13M | $3.03M |
| 其他非流动资产 | $26.01M | $26.14M | $25.72M | $25.72M | $26.03M |
| 负债合计 | $180.07M | $181.72M | $188.85M | $188.85M | $182.78M |
| 流动负债合计 | $30.77M | $31.78M | $38.30M | $38.30M | $37.41M |
| 应付款 | $652,000.00 | $6.39M | $7.86M | $7.86M | $6.29M |
| -应付账款 | $652,000.00 | $1.10M | $2.57M | $2.57M | $2.21M |
| -应付税款合计 | $0.00 | $5.29M | $5.29M | $5.29M | $4.07M |
| 一年内应计费用 | $19.32M | $14.64M | $19.50M | $19.50M | $20.21M |
| 短期债务及融资租赁负债 | $10.80M | $10.75M | $10.95M | $10.95M | $10.91M |
| -一年内到期融资租赁负债 | $10.80M | $10.75M | $10.95M | $10.95M | $10.91M |
| 非流动负债合计 | $149.30M | $149.94M | $150.55M | $150.55M | $145.37M |
| 长期应付账款及其他应付款 | $88.49M | $87.15M | $85.68M | $85.68M | $79.17M |
| 长期债务及融资租赁负债 | $27.77M | $29.75M | $31.76M | $31.76M | $33.68M |
| -长期融资租赁负债 | $27.77M | $29.75M | $31.76M | $31.76M | $33.68M |
| 其他非流动负债 | $33.04M | $33.04M | $33.11M | $33.11M | $32.53M |
| 股东权益合计 | $289.71M | $290.59M | $296.72M | $296.72M | $232.68M |
| 股东权益 | $289.71M | $290.59M | $296.72M | $296.72M | $232.68M |
| 股本 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -普通股 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -优先股 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 资本公积 | $1.16B | $1.16B | $1.16B | $1.16B | $1.15B |
| 留存收益 | -$870.46M | -$864.56M | -$859.63M | -$859.63M | -$920.65M |
| 不影响留存收益的损益 | -$76,000.00 | -$62,000.00 | $61,000.00 | $61,000.00 | $32,000.00 |
| -其他应收款 | – | – | $50.00M | $50.00M | – |
| -累计折旧 | – | – | -$23.82M | -$23.82M | – |
| -可供出售证券 | – | – | $11.13M | $11.13M | $3.03M |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 经营活动现金流 | -$6.97M | $73.28M | $238.54M | -$6.06M | -$6.51M |
| 持续经营经营活动现金流净额 | -$6.97M | $73.28M | $238.54M | -$6.06M | -$6.51M |
| 持续经营净利润 | -$5.90M | -$4.93M | $105.90M | $61.02M | $3.62M |
| 折旧、折耗与摊销 | $506,000.00 | $835,000.00 | $2.81M | $196,000.00 | $636,000.00 |
| 递延税款 | -$218,000.00 | -$3.00M | -$11.52M | $30,000.00 | $994,000.00 |
| 其他非现金项目 | $26,000.00 | $42,000.00 | $2.37M | $588,000.00 | $551,000.00 |
| 营运资金变动 | -$7.37M | $75.83M | $120.47M | -$72.38M | -$16.88M |
| -应收款变动 | -$4.80M | $79.95M | -$27.10M | -$77.27M | $3.65M |
| -预付资产变动 | -$1.25M | $1.67M | -$3.29M | -$814,000.00 | -$1.18M |
| -应付账款及应计费用变动 | -$1.05M | -$6.34M | $4.34M | -$3.11M | -$14.51M |
| -其他流动资产变动 | $330,000.00 | $1.34M | $143.09M | $223,000.00 | -$372,000.00 |
| -其他流动负债变动 | -$1.94M | -$2.27M | -$7.05M | -$1.89M | -$1.86M |
| -其他营运资金变动 | $1.33M | $1.47M | $10.48M | – | – |
| 投资活动现金流净额 | -$60.40M | $52.59M | -$105.28M | $588,000.00 | -$100.25M |
| 持续经营投资活动现金流净额 | -$60.40M | $52.59M | -$105.28M | $588,000.00 | -$100.25M |
| 投资购置及出售净额 | -$60.40M | $52.59M | -$105.24M | $596,000.00 | -$100.25M |
| 筹资活动现金流 | -$967,000.00 | -$5.58M | -$3.25M | -$1.49M | -$400,000.00 |
| 持续经营筹资活动现金流净额 | -$967,000.00 | -$5.58M | -$3.25M | -$1.49M | -$400,000.00 |
| 普通股发行净额 | -$2.10M | -$5.82M | -$4.01M | -$1.98M | -$678,000.00 |
| 股票期权行使所得 | $1.14M | $241,000.00 | $766,000.00 | $488,000.00 | $278,000.00 |
| 期末现金余额 | $220.60M | $288.94M | $168.64M | $168.64M | $175.61M |
| 现金净变动 | -$68.34M | $120.30M | $130.01M | -$6.97M | -$107.15M |
| 期初现金余额 | $288.94M | $168.64M | $38.63M | $175.61M | $282.76M |
| 自由现金流 | -$6.97M | $73.28M | $238.50M | -$6.07M | -$6.51M |
| 持续经营损益 | – | – | $35,000.00 | $0.00 | $0.00 |
| 固定资产购置及出售净额 | – | – | -$42,000.00 | -$8,000.00 | $0.00 |
暂无评论——快来第一个聊聊 TBPH。
登录后参与讨论。